Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide adjunct to insulin in adults with type 1 diabetes
NL-OMON38605Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Dec 2013
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of liraglutide in diabetes mellitus type 1 (T1D) (6 arms), sponsored by Novo Nordisk. Primary endpoints: Change from baseline in HbA1c after 52 weeks of treatment, Change from baseline in body weight after 52 weeks of treatment and 1 more. Started Dec 2013; status: active, not recruiting.
02
Drugs
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on NL-OMON38605.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38605.